Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Multiple Myeloma
In Patients with RRMM, Circularly Permuted TRAIL, a Novel TRAIL Agonist, Is Combined with Thalidomide and Dexamethasone
Read More
Multiple Myeloma
GMMG-HD6 Study: Bortezomib, Lenalidomide, and Dexamethasone with or without Elotuzumab for Patients with Newly Diagnosed MM
Read More
Multiple Myeloma
Isatuximab for Patients with Previously Treated AL Amyloidosis: A Phase 2 Study
Read More
Multiple Myeloma
IKEMA Interim Analysis: Depth of Response and Response Kinetics of Isatuximab plus Carfilzomib and Dexamethasone in Patients with RMM
Read More
Multiple Myeloma
ICARIA-MM Study: Isatuximab plus Pomalidomide and Dexamethasone in Patients with RRMM with Gain(1q21)
Read More
Multiple Myeloma
GMMG-Concept Trial: Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone in Treatment of Patients with High-Risk MM
Read More
Multiple Myeloma
Multiple Myeloma Year in Review Introduction
Read More
Multiple Myeloma
Selinexor Combined with Pomalidomide and Dexamethasone for Treatment of Patients with RRMM
Read More
Multiple Myeloma
In Patients with RRMM, Cobimetinib as a Single Agent and Combined with Venetoclax with or without Atezolizumab
Read More
Multiple Myeloma
In Patients with RRMM, Treatment with Venetoclax plus Daratumumab and Dexamethasone ± Bortezomib
Read More
1
2
3
4
Page 2 of 4
Results 11 - 20 of 31